A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

NCT07568535 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

GVHD - Graft-Versus-Host Disease

Interventions

DRUG: Remestemcel-L-rknd
OTHER: Placebo

Sponsor

Mesoblast, Ltd.